Benzinga | Mar 16, 2021 07:24AM EDT

Truist Securities Upgrades AnaptysBio to Buy, Raises Price Target to $34

Truist Securities analyst Joon Lee upgrades AnaptysBio (NASDAQ:ANAB) from Hold to Buy and raises the price target from $27 to $34.